Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Merck
AstraZeneca
UBS
Cantor Fitzgerald
Cipla
Boehringer Ingelheim

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 10,259,859

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,259,859
Title:Constructs having a SIRP-.alpha. domain or variant thereof
Abstract: The present disclosure features signal-regulatory protein .alpha. (SIRP-.alpha.) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-.alpha. constructs include a high affinity SIRP-.alpha. D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-.alpha.. The SIRP-.alpha. polypeptides or constructs include a SIRP-.alpha. D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein .alpha. (SIRP-.alpha.) D1 variant and (ii) an antibody.
Inventor(s): Pons; Jaume (San Carlos, CA), Deming; Laura (Palo Alto, CA), Goodman; Corey (Marshall, CA), Sim; Bang Janet (Brisbane, CA), Kauder; Steven Elliot (San Mateo, CA), Wan; Hong (Foster City, CA), Kuo; Tracy Chia-Chien (San Mateo, CA)
Assignee: ALX ONCOLOGY INC. (Burlingame, CA)
Application Number:15/230,186
Patent Claims:see list of patent claims

Details for Patent 10,259,859

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Sign Up ALX ONCOLOGY INC. (Burlingame, CA) 2035-08-07 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up ALX ONCOLOGY INC. (Burlingame, CA) 2035-08-07 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up ALX ONCOLOGY INC. (Burlingame, CA) 2035-08-07 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up ALX ONCOLOGY INC. (Burlingame, CA) 2035-08-07 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up ALX ONCOLOGY INC. (Burlingame, CA) 2035-08-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
Harvard Business School
McKesson
QuintilesIMS
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.